Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Sarah G Helton & Falk W Lohoff. (2015) Serotonin Pathway Polymorphisms and the Treatment of Major Depressive Disorder and Anxiety Disorders. Pharmacogenomics 16:5, pages 541-553.
Read now
Read now
Sneha Narasimhan & Falk W Lohoff. (2012) Pharmacogenetics of Antidepressant Drugs: Current Clinical Practice and Future Directions. Pharmacogenomics 13:4, pages 441-464.
Read now
Read now
Patricia Neafsey, Gary Ginsberg, Dale Hattis & Babasaheb Sonawane. (2009) Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity. Journal of Toxicology and Environmental Health, Part B 12:5-6, pages 334-361.
Read now
Read now
K. Mori, H. Hashimoto, H. Takatsu, M. Tsuda-Tsukimoto & T. Kume. (2009) Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 39:6, pages 415-422.
Read now
Read now
Laura K Schnackenberg, Jim Kaput & Richard D Beger. (2008) Metabolomics: A Tool for Personalizing Medicine?. Personalized Medicine 5:5, pages 495-504.
Read now
Read now
Susan Hurst, Cho-Ming Loi, Joanne Brodfuehrer & Ayman El-Kattan. (2007) Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opinion on Drug Metabolism & Toxicology 3:4, pages 469-489.
Read now
Read now
Nicola J. Hewitt, María José Gómez Lechón, J. Brian Houston, David Hallifax, Hayley S. Brown, Patrick Maurel, J. Gerald Kenna, Lena Gustavsson, Christina Lohmann, Christian Skonberg, Andre Guillouzo, Gregor Tuschl, Albert P. Li, Edward LeCluyse, Geny M. M. Groothuis & Jan G. Hengstler. (2007) Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies. Drug Metabolism Reviews 39:1, pages 159-234.
Read now
Read now
R. Mikstacka, A. M. Rimando, K. Szalaty, K. Stasik & W. Baer-Dubowska. (2006) Effect of natural analogues of -resveratrol on cytochromes P4501A2 and 2E1 catalytic activities. Xenobiotica 36:4, pages 269-285.
Read now
Read now
D Springer, R. F Staack, L. D Paul, T Kraemer & H. H Maurer. (2005) Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes. Xenobiotica 35:3, pages 227-237.
Read now
Read now
R. F. Staack, D. S. Theobald, L. D. Paul, D. Springer, T. Kraemer & H. H. Maurer. (2004) In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 34:2, pages 179-192.
Read now
Read now
D. Springer, R. F. Staack, L. D. Paul, T. Kraemer & H. H. Maurer. (2003) Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-α-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 33:10, pages 989-998.
Read now
Read now
T. Niwa, T. Shiraga, S. Yamasaki, K. Ishibashi, Y. Ohno & A. Kagayama. (2003) In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica 33:7, pages 717-729.
Read now
Read now
David F. V. Lewis, Sandeep Modi & Maurice Dickins. (2002) Structure–activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metabolism Reviews 34:1-2, pages 69-82.
Read now
Read now
G. G. Gibson, N. J. Plant, K. E. Swales, A. Ayrton & W. El-Sankary. (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:3, pages 165-206.
Read now
Read now
D. F. V. LEWIS, P. J. EDDERSHAW, P. S. GOLDFARB & M. H. TARBIT. (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102 : structural studies on specific CYP2D6substrate metabolism. Xenobiotica 27:4, pages 319-340.
Read now
Read now
Articles from other publishers (66)
Ayman El‐Kattan. 2023. Oral Bioavailability and Drug Delivery. Oral Bioavailability and Drug Delivery
677
700
.
Abiza Wali, Mashooq Ahmad Dar, Aarif Ali, Iyman Rasool, Lubna Tariq, Azher Arafah, Muneeb U. Rehman, Bashir Ahmad Malla & Adil Farooq Wali. 2023. Pharmacogenomics. Pharmacogenomics
169
194
.
Jia Jia. 2021. Cytochrome P450. Cytochrome P450
91
105
.
Christine L.H. Snozek & Loralie J. Langman. 2019. Critical Issues in Alcohol and Drugs of Abuse Testing. Critical Issues in Alcohol and Drugs of Abuse Testing
103
120
.
G. Gilardi. 2018. Encyclopedia of Interfacial Chemistry. Encyclopedia of Interfacial Chemistry
90
109
.
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
35
76
.
Xuan Lv, Liumeng Pan, Jiaying Wang, Liping Lu, Weilin Yan, Yanye Zhu, Yiwen Xu, Ming Guo & Shulin Zhuang. (2017) Effects of triazole fungicides on androgenic disruption and CYP3A4 enzyme activity. Environmental Pollution 222, pages 504-512.
Crossref
Crossref
Ingrid Friedl. 2013. Geriatrische Notfallversorgung. Geriatrische Notfallversorgung
473
488
.
Chun Li & Nataraj Kalyanaraman. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
189
212
.
Christine L. H. Snozek, Loralie J. Langman & Amitava Dasgupta. 2012. Pharmacogenomics in Clinical Therapeutics. Pharmacogenomics in Clinical Therapeutics
15
25
.
Ayman El‐Kattan, Susan Hurst, Joanne Brodfuehrer & Cho‐Ming Loi. 2011. Oral Bioavailability. Oral Bioavailability
253
265
.
James W. Paxton. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
22
.
David J. Greenblatt & Lisa L. von Moltke. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
625
649
.
Stefanie D. Krämer & Bernard Testa. (2009) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 6:10, pages 1477-1660.
Crossref
Crossref
Marilena Saraceno, Alessio Coi & Anna Maria Bianucci. (2008) Molecular modelling of human CYP2D6 and molecular docking of a series of ajmalicine- and quinidine-like inhibitors. International Journal of Biological Macromolecules 42:4, pages 362-371.
Crossref
Crossref
Frank T. Peters, Markus R. Meyer, Denis S. Theobald & Hans H. Maurer. (2008) Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4′-Methyl-α-pyrrolidinobutyrophenone. Drug Metabolism and Disposition 36:1, pages 163-168.
Crossref
Crossref
A. Serretti, A. Drago & Michael N Liebman. 2009. Biomarkers for Psychiatric Disorders. Biomarkers for Psychiatric Disorders
315
353
.
Iftekhar Mahmood & Marti Davi. Green. (2013) Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies. The Journal of Clinical Pharmacology 47:12, pages 1540-1554.
Crossref
Crossref
Tong Lin, Kristine Pan, Joyce Mordenti & Lin Pan. (2007) In vitro assessment of cytochrome P450 inhibition: Strategies for increasing LC/MS‐based assay throughput using a one‐point IC50 method and multiplexing high‐performance liquid chromatography. Journal of Pharmaceutical Sciences 96:9, pages 2485-2493.
Crossref
Crossref
María José Gómez-Lechón, José Vicente Castell & María Teresa Donato. (2007) Hepatocytes—the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo. Chemico-Biological Interactions 168:1, pages 30-50.
Crossref
Crossref
Shosaku Kashiwada, Maiko Kameshiro, Haruki Tatsuta, Yoshio Sugaya, Seth W. Kullman, David E. Hinton & Koichi Goka. (2007) Estrogenic modulation of CYP3A38, CYP3A40, and CYP19 in mature male medaka (Oryzias latipes). Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 145:3, pages 370-378.
Crossref
Crossref
Bernard Testa & Stefanie D. Krämer. (2007) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 4:3, pages 257-405.
Crossref
Crossref
Vikash Rajnikant Dodhia, Andrea Fantuzzi & Gianfranco Gilardi. (2006) Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego. JBIC Journal of Biological Inorganic Chemistry 11:7, pages 903-916.
Crossref
Crossref
Alexander Seifert, Stephan Tatzel, Rolf D. Schmid & Jürgen Pleiss. (2006) Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: The molecular basis of substrate binding and regioselectivity toward warfarin. Proteins: Structure, Function, and Bioinformatics 64:1, pages 147-155.
Crossref
Crossref
Rajanikanth Madabushi, Bruno Frank, Bernd Drewelow, Hartmut Derendorf & Veronika Butterweck. (2006) Hyperforin in St. John’s wort drug interactions. European Journal of Clinical Pharmacology 62:3, pages 225-233.
Crossref
Crossref
Anthony Atkinson, Jane R. Kenny & Ken Grime. (2005) AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS. Drug Metabolism and Disposition 33:11, pages 1637-1647.
Crossref
Crossref
Denise B. Serra, Melton B. Affrime, Martin P. Bedigian, Gerard Greig, Slavica Milosavljev, Andrej Skerjanec & Yibin Wang. (2013)
QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M
3
Selective Receptor Antagonist for the Treatment of Overactive Bladder
. The Journal of Clinical Pharmacology 45:9, pages 1038-1047.
Crossref
Crossref
Shosaku Kashiwada, David E. Hinton & Seth W. Kullman. (2005) Functional characterization of medaka CYP3A38 and CYP3A40: Kinetics and catalysis by expression in a recombinant baculovirus system. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 141:4, pages 338-348.
Crossref
Crossref
Jan M. Kriegl, Lennart Eriksson, Thomas Arnhold, Bernd Beck, Erik Johansson & Thomas Fox. (2005) Multivariate modeling of cytochrome P450 3A4 inhibition. European Journal of Pharmaceutical Sciences 24:5, pages 451-463.
Crossref
Crossref
Monette M Cotreau, Lisa L von Moltke & David J Greenblatt. (2005) The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates. Clinical Pharmacokinetics 44:1, pages 33-60.
Crossref
Crossref
Shin Umeda, Noriko Harakawa, Masanori Yamamoto & Koichi Ueno. (2005) Effect of Nonspecific Binding to Microsomes and Metabolic Elimination of Buprenorphine on the Inhibition of Cytochrome P4502D6. Biological and Pharmaceutical Bulletin 28:2, pages 212-216.
Crossref
Crossref
Thomas Kraemer, Thomas Pflugmann, Michael Bossmann, Nicole M Kneller, Frank T Peters, Liane D Paul, Dietmar Springer, Roland F Staack & Hans H Maurer. (2004) Fenproporex N-dealkylation to amphetamine—enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochemical Pharmacology 68:5, pages 947-957.
Crossref
Crossref
A Serretti & P Artioli. (2004) The pharmacogenomics of selective serotonin reuptake inhibitors. The Pharmacogenomics Journal 4:4, pages 233-244.
Crossref
Crossref
Iftekhar Mahmood. 2004. New Drug Development. New Drug Development
137
163
.
Roland F Staack, Liane D Paul, Dietmar Springer, Thomas Kraemer & Hans H Maurer. (2004) Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). Biochemical Pharmacology 67:2, pages 235-244.
Crossref
Crossref
John S. Markowitz, Jennifer L. Donovan, C. Lindsay DeVane, Laura Sipkes & Kenneth D. Chavin. (2003) Multiple-Dose Administration of Ginkgo biloba Did Not Affect Cytochrome P-450 2D6 or 3A4 Activity in Normal Volunteers. Journal of Clinical Psychopharmacology 23:6, pages 576-581.
Crossref
Crossref
J.Matthew Hutzler, Frank J Powers, Michael A Wynalda & Larry C Wienkers. (2003) Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species. Archives of Biochemistry and Biophysics 417:2, pages 165-175.
Crossref
Crossref
Dietmar Springer, Liane D. Paul, Roland F. Staack, Thomas Kraemer & Hans H. Maurer. (2003) IDENTIFICATION OF CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 4′-METHYL-α-PYRROLIDINOPROPIOPHENONE, A NOVEL SCHEDULED DESIGNER DRUG, IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition 31:8, pages 979-982.
Crossref
Crossref
Jennifer L. Donovan, C. Lindsay DeVane, Kenneth D. Chavin, Robin M. Taylor & John S. Markowitz. (2003)
Siberian Ginseng (
Eleutheroccus senticosus
) Effects on CYP2D6 and CYP3A4 Activity in Normal Volunteers
. Drug Metabolism and Disposition 31:5, pages 519-522.
Crossref
Crossref
Donald J. AbrahamBernard Testa & William Soine. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
431
498
.
Robert Z Harris, Graham R Jang & Shirley Tsunoda. (2003) Dietary Effects on Drug Metabolism and Transport. Clinical Pharmacokinetics 42:13, pages 1071-1088.
Crossref
Crossref
M. Teresa Donato & Jos?? V. Castell. (2003) Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism. Clinical Pharmacokinetics 42:2, pages 153-178.
Crossref
Crossref
Thomas D Nolin & Reginald F Frye. (2003) Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography–mass spectrometry. Journal of Chromatography B 783:1, pages 265-271.
Crossref
Crossref
Franz M. Belpaire & Mark G. Bogaert. 2003. The Practice of Medicinal Chemistry. The Practice of Medicinal Chemistry
501
515
.
Lisa L. von Moltke, James L. Weemhoff, Michael D. Perloff, Leah M. Hesse, Jerold S. Harmatz, Barbara F. Roth‐Schechter & David J. Greenblatt. (2002) Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P‐glycoprotein. Biopharmaceutics & Drug Disposition 23:9, pages 361-367.
Crossref
Crossref
Tashinga E Bapiro, Julia A Hasler, Marianne Ridderström & Collen M Masimirembwa. (2002) The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Biochemical Pharmacology 64:9, pages 1387-1398.
Crossref
Crossref
Thomas C. Dowling. (2016) Drug Metabolism Considerations in Patients With Chronic Kidney Disease. Journal of Pharmacy Practice 15:5, pages 419-427.
Crossref
Crossref
I. Mahmood,. (2002) Prediction of Clearance in Humans from In Vitro Human Liver Microsomes and Allometric Scaling. A Comparative Study of the Two Approaches. Drug Metabolism and Drug Interactions 19:1, pages 49-64.
Crossref
Crossref
Feng Gao, Diane L. Johnson, Sean Ekins, John Janiszewski, Kevin G. Kelly, R. Daniel Meyer & Michael West. (2002) Optimizing Higher Throughput Methods to Assess Drug–Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50. SLAS Discovery 7:4, pages 373-382.
Crossref
Crossref
Hye Chin Chung, So Hee Kim, Myung Gull Lee & Sang Geon Kim. (2002) Increase in Urea in Conjunction with l-Arginine Metabolism in the Liver Leads to Induction of Cytochrome P450 2E1 (CYP2E1): The Role of Urea in CYP2E1 Induction by Acute Renal Failure. Drug Metabolism and Disposition 30:6, pages 739-746.
Crossref
Crossref
Wenjiang Zhang, Yamini Ramamoorthy, Tansel Kilicarslan, Helma Nolte, Rachel F. Tyndale & Edward M. Sellers. (2002) Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives. Drug Metabolism and Disposition 30:3, pages 314-318.
Crossref
Crossref
Charlotte Herrlinger & Ulrich Klotz. (2001) Drug metabolism and drug interactions in the elderly. Best Practice & Research Clinical Gastroenterology 15:6, pages 897-918.
Crossref
Crossref
Su-Jun Lee, Olaf R. Hedstrom, Kay Fischer, Jun-Lan Wang-Buhler, Alaattin Sen, Ismet Cok & Donald R. Buhler. (2001) Immunohistochemical Localization and Differential Expression of Cytochrome P450 3A27 in the Gastrointestinal Tract of Rainbow Trout. Toxicology and Applied Pharmacology 177:2, pages 94-102.
Crossref
Crossref
David Lewis. 2001. Guide to Cytochromes P450. Guide to Cytochromes P450
164
210
.
I. Mahmood,. (2001) Interspecies Scaling: Is a priori Knowledge of Cytochrome P450 Isozymes Involved in Drug Metabolism Helpful in Prediction of Clearance in Humans from Animal Data?. Drug Metabolism and Drug Interactions 18:2, pages 135-148.
Crossref
Crossref
Timothy W. Synold, Isabelle Dussault & Barry Marc Forman. (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Medicine 7:5, pages 584-590.
Crossref
Crossref
Pascal Bonnabry, Johann Sievering, Thierry Leemann & Pierre Dayer. (2001) Quantitative Drug Interactions Prediction System (Q-DIPS). Clinical Pharmacokinetics 40:9, pages 631-640.
Crossref
Crossref
D.A Smith. (2000) Induction and drug development. European Journal of Pharmaceutical Sciences 11:3, pages 185-189.
Crossref
Crossref
Craig Sams, Howard J Mason & Roger Rawbone. (2000) Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicology Letters 116:3, pages 217-221.
Crossref
Crossref
Margherita Strolin Benedetti. (2009) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundamental & Clinical Pharmacology 14:4, pages 301-319.
Crossref
Crossref
Sean Ekins, Barbara J. Ring, James Grace, Donna J. McRobie-Belle & Steven A. Wrighton. (2000) Present and future in vitro approaches for drug metabolism. Journal of Pharmacological and Toxicological Methods 44:1, pages 313-324.
Crossref
Crossref
Kazuhiko Motoba, Hideo Nishizawa, Takashi Suzuki, Hiroshi Hamaguchi, Matazaemon Uchida & Shunji Funayama. (2000) Species-Specific Detoxification Metabolism of Fenpyroximate, a Potent Acaricide. Pesticide Biochemistry and Physiology 67:2, pages 73-84.
Crossref
Crossref
Thomas Thum & Jürgen Borlak. (2000) Gene expression in distinct regions of the heart. The Lancet 355:9208, pages 979-983.
Crossref
Crossref
Monette M Cotreau, Lisa L von Moltke, Margery C Beinfeld & David J Greenblatt. (2000) Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. Journal of Pharmacological and Toxicological Methods 43:1, pages 41-54.
Crossref
Crossref
J.S. Markowitz, C.L. DeVane, D.W. Boulton, S.W. Carson, Z. Nahas & S.C. Risch. (2000) Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sciences 66:9, pages PL133-PL139.
Crossref
Crossref
Ryotaro Azuma, Masahito Komuro, Sherry R Black & James M Mathews. (1999) The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat. Toxicology Letters 110:3, pages 137-144.
Crossref
Crossref